Lumos Diagnostics Expands Development Agreement with Hologic for Enhanced fFN Test

Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has issued an announcement.

Lumos Diagnostics has announced an expansion in the scope of its Development Agreement with Hologic, Inc. for a new fetal fibronectin test, which will now include additional hardware features in Phase 3. This expansion is expected to generate additional revenue of US$0.6 – US$0.8 million for Lumos, with the total value of the agreement now estimated between US$5.3 – US$5.5 million. The project, which spans three phases, is progressing well, with Phase 2 expected to complete by April 2025 and the entire project by December 2025. This development enhances Lumos’s industry positioning by delivering a more feature-rich product in collaboration with Hologic, potentially benefiting stakeholders through improved diagnostic capabilities.

More about Lumos Diagnostics Holdings Ltd.

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. The company offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also develops, manufactures, and commercializes novel Lumos-branded point-of-care tests targeting infectious and inflammatory diseases.

YTD Price Performance: -25.71%

Average Trading Volume: 1,941,656

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$19.46M

For an in-depth examination of LDX stock, go to TipRanks’ Stock Analysis page.